These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 31926212)

  • 1. Stromal PD-1
    Chen L; Cao MF; Xiao JF; Ma QH; Zhang H; Cai RL; Miao JY; Wang WY; Zhang H; Luo M; Ping YF; Yao XH; Cui YH; Zhang X; Bian XW
    Hum Pathol; 2020 Mar; 97():68-79. PubMed ID: 31926212
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Infiltration of tumor-associated macrophages is involved in tumor programmed death-ligand 1 expression in early lung adenocarcinoma.
    Shima T; Shimoda M; Shigenobu T; Ohtsuka T; Nishimura T; Emoto K; Hayashi Y; Iwasaki T; Abe T; Asamura H; Kanai Y
    Cancer Sci; 2020 Feb; 111(2):727-738. PubMed ID: 31821665
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The intratumoral distribution influences the prognostic impact of CD68- and CD204-positive macrophages in non-small cell lung cancer.
    Li Z; Maeda D; Yoshida M; Umakoshi M; Nanjo H; Shiraishi K; Saito M; Kohno T; Konno H; Saito H; Minamiya Y; Goto A
    Lung Cancer; 2018 Sep; 123():127-135. PubMed ID: 30089583
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Upregulation of PD-L1 by SPP1 mediates macrophage polarization and facilitates immune escape in lung adenocarcinoma.
    Zhang Y; Du W; Chen Z; Xiang C
    Exp Cell Res; 2017 Oct; 359(2):449-457. PubMed ID: 28830685
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of immune-related gene signature predicting survival in the tumor microenvironment of lung adenocarcinoma.
    Zhao M; Li M; Chen Z; Bian Y; Zheng Y; Hu Z; Liang J; Huang Y; Yin J; Zhan C; Feng M; Wang Q
    Immunogenetics; 2020 Dec; 72(9-10):455-465. PubMed ID: 33188484
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of scavenger receptor MARCO defines a targetable tumor-associated macrophage subset in non-small cell lung cancer.
    La Fleur L; Boura VF; Alexeyenko A; Berglund A; Pontén V; Mattsson JSM; Djureinovic D; Persson J; Brunnström H; Isaksson J; Brandén E; Koyi H; Micke P; Karlsson MCI; Botling J
    Int J Cancer; 2018 Oct; 143(7):1741-1752. PubMed ID: 29667169
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Deciphering the heterogeneity dominated by tumor-associated macrophages for survival prognostication and prediction of immunotherapy response in lung adenocarcinoma.
    Sun J; Guo H; Nie Y; Zhou S; Zeng Y; Sun Y
    Sci Rep; 2024 Apr; 14(1):9276. PubMed ID: 38653742
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FAM83A drives PD-L1 expression via ERK signaling and FAM83A/PD-L1 co-expression correlates with poor prognosis in lung adenocarcinoma.
    Zhou F; Wang X; Liu F; Meng Q; Yu Y
    Int J Clin Oncol; 2020 Sep; 25(9):1612-1623. PubMed ID: 32430734
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic impact of programmed death-ligand 1 expression in correlation with human leukocyte antigen class I expression status in stage I adenocarcinoma of the lung.
    Hirai A; Yoneda K; Shimajiri S; Kuroda K; Hanagiri T; Fujino Y; Tanaka F
    J Thorac Cardiovasc Surg; 2018 Jan; 155(1):382-392.e1. PubMed ID: 28711324
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical Significance of PD-L1 Expression in Both Cancer and Stroma Cells of Cholangiocarcinoma Patients.
    Kitano Y; Yamashita YI; Nakao Y; Itoyama R; Yusa T; Umezaki N; Tsukamoto M; Yamao T; Miyata T; Nakagawa S; Okabe H; Imai K; Chikamoto A; Ishiko T; Baba H
    Ann Surg Oncol; 2020 Feb; 27(2):599-607. PubMed ID: 31407173
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic Significance of Programmed Cell Death Ligand 1 (PD-L1), CD8+ Tumor-Infiltrating Lymphocytes and p53 in Non-Small Cell Lung Cancer: An Immunohistochemical Study.
    Rashed HE; Abdelrahman AE; Abdelgawad M; Balata S; Shabrawy ME
    Turk Patoloji Derg; 2017; 1(1):211-222. PubMed ID: 28832075
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PD-L1 expression is associated with epithelial-to-mesenchymal transition in adenocarcinoma of the lung.
    Kim S; Koh J; Kim MY; Kwon D; Go H; Kim YA; Jeon YK; Chung DH
    Hum Pathol; 2016 Dec; 58():7-14. PubMed ID: 27473266
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PD-L1 expression on tumor-infiltrating immune cells is highly associated with M2 TAM and aggressive malignant potential in patients with resected non-small cell lung cancer.
    Sumitomo R; Hirai T; Fujita M; Murakami H; Otake Y; Huang CL
    Lung Cancer; 2019 Oct; 136():136-144. PubMed ID: 31499335
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of PD-L1 expression and PD-L1 gene polymorphism with poor prognosis in lung adenocarcinoma and squamous cell carcinoma.
    Yeo MK; Choi SY; Seong IO; Suh KS; Kim JM; Kim KH
    Hum Pathol; 2017 Oct; 68():103-111. PubMed ID: 28851662
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Abundant tumor promoting stromal cells in lung adenocarcinoma with hypoxic regions.
    Nakamura H; Ichikawa T; Nakasone S; Miyoshi T; Sugano M; Kojima M; Fujii S; Ochiai A; Kuwata T; Aokage K; Suzuki K; Tsuboi M; Ishii G
    Lung Cancer; 2018 Jan; 115():56-63. PubMed ID: 29290263
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumour-associated macrophages are associated with poor prognosis and programmed death ligand 1 expression in oesophageal cancer.
    Yagi T; Baba Y; Okadome K; Kiyozumi Y; Hiyoshi Y; Ishimoto T; Iwatsuki M; Miyamoto Y; Yoshida N; Watanabe M; Komohara Y; Baba H
    Eur J Cancer; 2019 Apr; 111():38-49. PubMed ID: 30822683
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical significance of PD-L1-positive cancer-associated fibroblasts in pN0M0 non-small cell lung cancer.
    Teramoto K; Igarashi T; Kataoka Y; Ishida M; Hanaoka J; Sumimoto H; Daigo Y
    Lung Cancer; 2019 Nov; 137():56-63. PubMed ID: 31546072
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Spatial Density and Distribution of Tumor-Associated Macrophages Predict Survival in Non-Small Cell Lung Carcinoma.
    Zheng X; Weigert A; Reu S; Guenther S; Mansouri S; Bassaly B; Gattenlöhner S; Grimminger F; Pullamsetti S; Seeger W; Winter H; Savai R
    Cancer Res; 2020 Oct; 80(20):4414-4425. PubMed ID: 32699134
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sarcomatoid lung carcinomas show high levels of programmed death ligand-1 (PD-L1) and strong immune-cell infiltration by TCD3 cells and macrophages.
    Vieira T; Antoine M; Hamard C; Fallet V; Duruisseaux M; Rabbe N; Rodenas A; Cadranel J; Wislez M
    Lung Cancer; 2016 Aug; 98():51-58. PubMed ID: 27393506
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Combination of MEK Inhibitor With Immunomodulatory Antibodies Targeting Programmed Death 1 and Programmed Death Ligand 1 Results in Prolonged Survival in Kras/p53-Driven Lung Cancer.
    Lee JW; Zhang Y; Eoh KJ; Sharma R; Sanmamed MF; Wu J; Choi J; Park HS; Iwasaki A; Kaftan E; Chen L; Papadimitrakopoulou V; Herbst RS; Koo JS
    J Thorac Oncol; 2019 Jun; 14(6):1046-1060. PubMed ID: 30771521
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.